This guide is currently available in English. A Spanish version is in progress.
Sourcing Exosomes in Arkansas
Licensed Arkansas practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Arkansas buyers need their own professional license and NPI; the wholesale distributor permit is the supplier’s obligation, not the purchaser’s.
Arkansas turns up in regenerative medicine conversations for a law that is not what it sounds like: the Emerging Therapies Act of 2017 directed the state employee health plan to explore coverage of regenerative injection therapies, and it authorized no clinical service. What actually shapes practice here is the nurse practitioner independence pathway created in 2021.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Arkansas? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material. Compounded preparations are not available in this state at this time |
| Last reviewed | 16 October 2026 |
Ordering from Arkansas
ExaVeyra ships to licensed practices in all 50 states, Arkansas included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Arkansas professional license in good standing, verifiable through the Arkansas State Medical Board license verification or the Arkansas State Board of Nursing nurse portal.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- An Arkansas sales and use tax permit and resale exemption documentation through the Department of Finance and Administration if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Arkansas permits wholesale distributors through the State Board of Pharmacy, which now sits administratively within the Department of Health. The trigger is broad: every wholesale distributor engaged in the wholesale distribution of prescription drugs, including manufacturing in the state, shipping into the state, or selling or offering to sell in the state, registers annually with the Board for a permit, and Board Rule 8 extends the same framework to third-party logistics providers, manufacturers, and outsourcing facilities. The permit sits with the distributor shipping in, not with the purchasing practice.
Ark. Code Ann. § 20-64-505; Arkansas State Board of Pharmacy Rule 8 · Arkansas State Board of Pharmacy
Arkansas regenerative-medicine law
Arkansas has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
No Arkansas statute addresses unapproved regenerative therapy, so federal law is the only layer that governs it here. Two adjacent laws cause regular confusion. The Arkansas Right to Try Act (SB 4, Act 374 of 2015, the seventh state to enact one) lets a terminally ill patient access an investigational drug, biological product, or device past Phase 1 trials; it is a terminal-illness access law, not a stem cell authorization. The Emerging Therapies Act of 2017 (HB 2014, Act 1089) required the State and Public School Life and Health Insurance Board to explore emerging therapies and the cost-effectiveness of treatment, which brought regenerative injection therapies into the state employee health plan conversation; it is a coverage-study mandate, and it neither permits nor conditions any clinical service. Practice in this area is governed by the Medical Practice Act, the Nurse Practice Act, and the boards that administer them, alongside federal law.
How this applies to exosomes
Arkansas has not enacted a stem cell authorization law like Florida, Texas, or Georgia, a disclosure law like California, or a documentation statute like Tennessee. The Emerging Therapies Act of 2017 is sometimes cited as though it were one; it directed a state insurance board to study coverage and authorizes no clinical service, so there is no Arkansas definition to read exosomes into or out of. Exosomes are acellular extracellular vesicles, a category even the cell-focused statutes of other states do not reach. Exosome products in Arkansas are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Arkansas practice
Arkansas splits advanced practice oversight across agencies on purpose: the Full Independent Practice Credentialing Committee that reviews CNP independence applications is made up of physicians and nurse practitioners and works with both the State Medical Board and the State Board of Nursing, meeting at least quarterly. A practice led by a CNP without the full independence credential keeps its collaborative practice agreement current, and applications and renewals run through the Arkansas Nurse Portal.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Arkansas State Medical Board may perform medical acts within their scope and are the source of any delegation; the Board maintains a physician and physician assistant delegation rule governing what may be assigned and under what oversight. |
| NP / APRN | Certified nurse practitioners begin under a collaborative practice agreement with a physician. After 6,240 hours of practice under such an agreement, a CNP may apply to the Full Independent Practice Credentialing Committee for a full independent practice credential (Act 412 of 2021), submitting recommendation letters, a notarized hours affidavit, and advanced pharmacology continuing education; the credential renews every three years. Act 872 of 2023 extended the pathway to clinical nurse specialists. |
| PA | Physician assistants are licensed by the Arkansas State Medical Board and practice under physician delegation within the Board’s delegation rule. |
| RN | Registered nurses may perform delegated treatments within their scope and under an order from a provider with authority to issue one, after that provider has evaluated the patient. An RN does not diagnose, prescribe, or independently select a treatment. |
Good faith examination
Arkansas expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. That provider can be a physician or a nurse practitioner practicing within its credential, collaborative or independent. Confirm current expectations with the Arkansas State Medical Board and the Arkansas State Board of Nursing, since this area is governed by board rules and interpretation.
Ownership and clinic licensing
Arkansas does not codify a corporate practice of medicine prohibition of the Texas or New York kind, and physician-owned professional entities alongside management services arrangements are the usual structures. Because the position is not a bright-line statutory rule, published summaries disagree with one another, so treat ownership structure as a question for Arkansas counsel and the licensing boards rather than one a guide should answer with a percentage.
Cold chain into Arkansas
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Arkansas order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Little Rock | Pulaski | Capital and the state’s largest medical market. |
| Fayetteville | Washington | Northwest Arkansas corridor anchor with a university presence. |
| Bentonville and Rogers | Benton | Fast-growing corporate corridor in the state’s northwest. |
| Fort Smith | Sebastian | Western border market serving eastern Oklahoma. |
| Jonesboro | Craighead | Northeast Arkansas hub with a regional medical base. |
| Hot Springs | Garland | Resort market with a long wellness tradition. |
- Arkansas orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Each shipment arrives with the manufacturer’s handling instructions and the lot’s Certificate of Analysis; store to the labeled conditions on arrival.
Practice types we supply in Arkansas
Arkansas licensing and verification
Arkansas State Medical Board
Licenses physicians and physician assistants, with online license verification.
Arkansas State Board of Nursing
Licenses RNs and APRNs; applications run through the Arkansas Nurse Portal.
Arkansas State Board of Pharmacy
Issues the wholesale distributor permits held by suppliers shipping into Arkansas.
Arkansas Department of Finance and Administration
Sales and use tax permits and resale documentation through the ATAP portal.
Arkansas sourcing questions
- Does Arkansas have a stem cell law?
- Not a practice law. The Emerging Therapies Act of 2017 (Act 1089) is the statute usually meant by the question, and it directed the State and Public School Life and Health Insurance Board to explore emerging therapies and cost-effectiveness of treatment: a coverage-study mandate for the state employee health plan, not an authorization to practice. Arkansas also has a plain right-to-try law (Act 374 of 2015) for terminal illness. Neither authorizes or conditions a clinical service, so exosome products in Arkansas are governed by federal law, under which no exosome product is FDA-approved for administration to humans.
- What did the Arkansas Emerging Therapies Act of 2017 actually do?
- HB 2014, which became Act 1089 of 2017, required the State and Public School Life and Health Insurance Board to explore emerging therapies and the cost-effectiveness of treatment, which brought regenerative injection therapies into the state employee health plan conversation. It is frequently summarized as Arkansas embracing regenerative medicine, but the statute is a study and coverage mandate directed at an insurance board. It neither permits nor restricts anything in a clinic.
- Can a nurse practitioner run a practice in Arkansas without a physician?
- Yes, once credentialed. Act 412 of 2021 created a pathway: after 6,240 hours of practice under a collaborative practice agreement, a certified nurse practitioner applies to the Full Independent Practice Credentialing Committee with recommendation letters, a notarized hours affidavit, and advanced pharmacology continuing education. The committee reviews applications at least quarterly, and the credential renews every three years. Act 872 of 2023 extended the pathway to clinical nurse specialists. Until credentialed, the collaborative practice agreement applies.
- Does my Arkansas clinic need a wholesale distributor permit to buy exosomes?
- No. The wholesale distributor permit under Ark. Code Ann. 20-64-505 and Board of Pharmacy Rule 8 is held by the distributor shipping into Arkansas, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, and the FDA said so directly in its 2019 public safety notification on exosome products. ExaVeyra supplies Kimera exosome material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot traceability on every vial.
- How long does cold-chain shipping take to Arkansas?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- Arkansas HB 2014 (2017), Emerging Therapies Act, Act 1089, bill record (accessed 16 October 2026)
- Arkansas State Board of Pharmacy (Department of Health) (accessed 16 October 2026)
- Arkansas State Board of Nursing, advanced practice information (accessed 16 October 2026)
- Arkansas Full Independent Practice Credentialing Committee (accessed 16 October 2026)
- Arkansas State Medical Board (accessed 16 October 2026)
- Arkansas Department of Finance and Administration (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: Defines the current characterization and reporting standard for extracellular vesicles, the benchmark behind the COA and lot documentation this page describes.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: ISEV position on manufacturing and safety documentation for EV-based products in trials, supporting this page’s framing that clinical use runs through regulated research.
- Phinney DG, Pittenger MF. Concise Review: MSC-Derived Exosomes for Cell-Free Therapy. Stem Cells, 2017. doi:10.1002/stem.2575 PMID:28294454Narrative reviewsupports: Reviews mesenchymal stromal cells as a source of exosomes, context for the perinatal MSC-derived EV source material this page describes.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.